Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 29, 2025 08:30 ET | Source: PolyPid Ltd.

PolyPid to Report Third Quarter 2025 Financial Results and Operational Highlights on November 12, 2025

PETACH TIKVA, Israel, Oct. 29, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today...
September 30, 2025 08:45 ET | Source: PolyPid Ltd.

PolyPid to Present Its Positive Phase 3 SHIELD II Topline Results at the 2025 American College of Surgeons Clinical Congress

PETACH TIKVA, Israel, Sept. 30, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced...
September 16, 2025 08:30 ET | Source: PolyPid Ltd.

PolyPid Successfully Completes Israeli Ministry of Health GMP Inspection, Advancing Towards Commercial Manufacturing Readiness for D-PLEX₁₀₀

PETACH TIKVA, Israel, Sept. 16, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced...
September 03, 2025 08:30 ET | Source: PolyPid Ltd.

PolyPid to Participate in the Upcoming 27th Annual H.C. Wainwright Global Investment Conference

PETACH TIKVA, Israel, Sept. 03, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today...
September 02, 2025 08:30 ET | Source: PolyPid Ltd.

PolyPid to Present at the 14th Meeting of the Israel Controlled Release Society Conference

PETACH TIKVA, Israel, Sept. 02, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today...
August 13, 2025 07:30 ET | Source: PolyPid Ltd.

PolyPid Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Positive Phase 3 SHIELD II Trial Results - D-PLEX₁₀₀ successfully met its primary efficacy endpoint and demonstrated 58% reduction in SSI NDA submission expected in Q1 2026 Unveiled a Long-Acting...
August 12, 2025 08:00 ET | Source: PolyPid Ltd.

PolyPid Appoints Dr. Nurit Tweezer-Zaks as Chief Medical Officer

PETACH TIKVA, Israel, Aug. 12, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced...
July 30, 2025 08:00 ET | Source: PolyPid Ltd.

PolyPid to Report Second Quarter 2025 Financial Results and Operational Highlights on August 13, 2025

PETACH TIKVA, Israel, July 30, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced...
July 15, 2025 10:00 ET | Source: The Finance Herald

Finance Herald Publishes Coverage of PolyPid's Groundbreaking New 60-Day GLP-1 Delivery Tech

New York, July 15, 2025 (GLOBE NEWSWIRE) -- The Finance Herald, a leading news and analysis site today published a new deep dive report covering market developments, with a focus on PolyPid and...
July 15, 2025 08:00 ET | Source: PolyPid Ltd.

PolyPid Unveils a Long-Acting GLP-1 Receptor Agonists Delivery Platform Targeting the Diabetes and Weight Loss Market

PolyPid's proprietary and clinically validated, prolonged-release drug delivery technology aims to subcutaneously deliver GLP-1 for approximately 60 days, compared to current standard of care of...